Inovio Pharmaceuticals (NASDAQ:INO) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) to a sell rating in a report published on Friday morning.

A number of other analysts have also weighed in on INO. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 19th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, HC Wainwright restated a “neutral” rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.20.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.92 on Friday. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The stock has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.92. The company has a fifty day moving average of $2.04 and a 200-day moving average of $3.67.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18. The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Deep Track Capital LP raised its position in Inovio Pharmaceuticals by 72.9% during the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock worth $5,708,000 after buying an additional 1,314,796 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 4th quarter worth approximately $1,922,000. AIGH Capital Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $1,197,000. Bank of America Corp DE grew its stake in Inovio Pharmaceuticals by 1,035.2% in the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock valued at $1,173,000 after acquiring an additional 584,521 shares during the period. Finally, Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 6,874 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.